Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:NPPB)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteUnits(range)
ST000546 AN000832 Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant Plasmodium Cells Plasmodium falciparum Malaria Monash Institute of Pharmaceutical Sciences, Monash University Peak height
ST000421 AN000663 ms3076 T1D poor glycemic control and control samples Blood Human Diabetes Mayo Clinic Peak intensity
ST000422 AN000667 Type 1 Diabetes good glycemic control and controls samples Blood Human Diabetes Mayo Clinic Peak intensity
ST000422 AN000669 Type 1 Diabetes good glycemic control and controls samples Blood Human Diabetes Mayo Clinic Peak intensity
ST001201 AN001998 Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Human Malaria Monash University Peak intensity
ST001201 AN001998 Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University Peak intensity
ST001202 AN002000 Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites Cultured cells Human Malaria Monash University Peak intensity
ST001202 AN002000 Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University Peak intensity
ST001204 AN002004 Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Human Malaria Monash University Peak intensity
ST001204 AN002004 Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University Peak intensity
ST001205 AN002006 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Human Malaria Monash University Peak intensity
ST001205 AN002006 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University Peak intensity
ST002094 AN003420 Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) Feces Human Irritable bowel syndrome Mayo Clinic raw intensity
ST002094 AN003421 Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) Feces Human Irritable bowel syndrome Mayo Clinic raw intensity
ST000046 AN000076 Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) Blood Human Alzheimers disease Mayo Clinic Raw MS Intensities
ST000046 AN000077 Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) Blood Human Alzheimers disease Mayo Clinic Raw MS Intensities
ST002108 AN003448 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) Blood Plasmodium falciparum Malaria Monash University relative intensity
ST001175 AN001950 Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparum Plasmodium cells Plasmodium falciparum Malaria Monash University Signal Intensity
  logo